Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab in Recurrent Malignant Glioma
NCT02794883Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Nov 2016
- Primary completion
- May 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tremelimumab and durvalumab in glioblastoma (GBM) (3 arms), sponsored by Northwestern University. Primary endpoint: T-cell (Immunologic) Changes in Blood. Started Nov 2016; status: completed.
02
Drugs
tremelimumabdurvalumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02794883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794883.